Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia

Blood (2024) 144 (16): 1689–1698.

https://doi.org/10.1182/blood.2024024952

Published: 2024

Includes: Supplemental data

Journal Articles

Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease

Blood (2020) 135 (1): 28–40.

https://doi.org/10.1182/blood.2019000032

Published: 2020

Includes: Supplemental data

Journal Articles

Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease

Blood (2019) 133 (1): 94–99.

https://doi.org/10.1182/blood-2018-03-839993

Published: 2019

Journal Articles

Ibrutinib for chronic graft-versus-host disease after failure of prior therapy

David Miklos, Corey S. Cutler, Mukta Arora, Edmund K. Waller, Madan Jagasia, Iskra Pusic, Mary E. Flowers, Aaron C. Logan, Ryotaro Nakamura, Bruce R. Blazar, Yunfeng Li, Stephen Chang, Indu Lal, Jason Dubovsky, Danelle F. James, Lori Styles, Samantha Jaglowski

Blood (2017) 130 (21): 2243–2250.

https://doi.org/10.1182/blood-2017-07-793786

Published: 2017

Includes: Supplemental data

Journal Articles

Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-β production

Blood (2017) 129 (18): 2570–2580.

https://doi.org/10.1182/blood-2017-01-758854

Published: 2017

Includes: Supplemental data

Journal Articles

Allogeneic Transplants from HLA-Mismatched Unrelated Donors Using Total Lymphoid Irradiation and Antithymocyte Globulin Conditioning Retain a Low Risk of Graft-Versus-Host Disease and Non-Relapse Mortality with at Least As Potent Anti-Tumor Activity As with Matched Unrelated Donors

Michael A. Spinner, MD, Marcelo Fernandez Vina, PhD, Linda Elder, BA, Sally Arai, MD, Laura Johnston, MD, Everett Meyer, MD PhD, David Miklos, MD PhD, Lori Muffly, MD, Robert S. Negrin, MD, Judith Shizuru, MD PhD, Wen-Kai Weng, MD PhD, Ginna G. Laport, MD, Samuel Strober, MD, Robert Lowsky, MD, Andrew R. Rezvani, MD

Blood (2016) 128 (22): 4669.

https://doi.org/10.1182/blood.V128.22.4669.4669

Published: 2016

Journal Articles

A Phase I Study of Donor Regulatory T Cells As Treatment for Steroid Dependent/Refractory Chronic Graft Versus Host Disease

Laura Johnston, MD, Randall Armstrong, Jeanette Baker, PhD, Bita Sahaf, Joanne Otani, Keri Tate, PhD, Cynthia Tudisco, Kevin Sheehan, PhD, Everett Meyer, MD PhD, David Miklos, MD PhD, Robert S. Negrin, MD

Blood (2016) 128 (22): 385.

https://doi.org/10.1182/blood.V128.22.385.385

Published: 2016

Journal Articles

Multicenter Open-Label Phase 2 Study of Ibrutinib in Chronic Graft Versus Host Disease (cGVHD) after Failure of Corticosteroids

David Miklos, MD, Corey S. Cutler, MD MPH, Mukta Arora, MD, Edmund K. Waller, MD PhD FACP, Madan Jagasia, MD MBBS, MS, Iskra Pusic, MD, Mary E. Flowers, MD, Aaron C. Logan, MD PhD, Ryotaro Nakamura, MD, Bruce R. Blazar, MD, Yunfeng Li, PhD, Indu Lal, MD, Jason Dubovsky, PhD, Danelle F. James, MD, Lori Styles, MD, Samantha Jaglowski, MD PhD

Blood (2016) 128 (22): LBA-3.

https://doi.org/10.1182/blood.V128.22.LBA-3.LBA-3

Published: 2016

Journal Articles

Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematologic Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation

Lori S. Muffly, MDMS, Kevin Sheehan, PhD, Randall Armstrong, Keri Tate, PhD, Cynthia Tudisco, Andrew R. Rezvani, MD, David Miklos, MD PhD, Sally Arai, MD, Judith Shizuru, MD PhD, Laura Johnston, Everett Meyer, MD PhD, Wen-Kai Weng, MD PhD, Ginna G. Laport, MD, Robert S Negrin, MD, Sam Strober, Robert Lowsky, MD

Blood (2016) 128 (22): 4615.

https://doi.org/10.1182/blood.V128.22.4615.4615

Published: 2016

Journal Articles

Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1

Blood (2016) 128 (22): LBA-6.

https://doi.org/10.1182/blood.V128.22.LBA-6.LBA-6

Published: 2016

Journal Articles

Donor-Derived CIK Cell Infusion As Consolidative Therapy after Non-Myeloablative Allogeneic Transplant in Patients with Myeloid Neoplasms

Blood (2015) 126 (23): 3232.

https://doi.org/10.1182/blood.V126.23.3232.3232

Published: 2015

Journal Articles

Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing

Blood (2015) 125 (24): 3679–3687.

https://doi.org/10.1182/blood-2015-03-635169

Published: 2015

Includes: Supplemental data

Journal Articles

Chronic Graft-Versus-Host Disease Responds to Imatinib and Pre Transplant/Donor Anti-PDGFRA Antibodies Predict for Chronic Graft-Versus-Host Disease Development

George L. Chen, MD, Sally Arai, MD, Mary E.D. Flowers, MD, Joanne M Otani, RN, MSN, BS, Marc Coram, PhD, Alex McMillan, PhD, Judith A Shizuru, PhD, MD, Laura Johnston, MD, David Miklos, MD, PhD

Blood (2010) 116 (21): 2320.

https://doi.org/10.1182/blood.V116.21.2320.2320

Published: 2010

Journal Articles

Protein Microarrays Identify Elevated Allogeneic Antibodies In Association with Extensive Chronic Graft Versus Host Disease

John F. Tan, MD, George L. Chen, MD, Persis P. Wadia, PhD, Marc Coram, PhD, David Miklos, MD, PhD

Blood (2010) 116 (21): 2344.

https://doi.org/10.1182/blood.V116.21.2344.2344

Published: 2010

Journal Articles

Chronic Gvhd Global Severity According to NIH Consensus Criteria: Results From the Chronic Gvhd Consortium

Sally Arai, MD, Madan Jagasia, MD, MS, Mukta Arora, MD, David Miklos, MD, PhD, Xiaoyu Chai, MS, Barry Storer, PhD, Paul J. Martin, Corey Cutler, MD, MPH, FRCPC, Daniel J. Weisdorf, MD, Joseph Pidala, Jeanne Palmer, MD, Mary Flowers, MD, David Jacobsohn, MD, Paul A. Carpenter, Steven Z. Pavletic, MD, Georgia B. Vogelsang, MD, Stephanie J. Lee

Blood (2010) 116 (21): 220.

https://doi.org/10.1182/blood.V116.21.220.220

Published: 2010

Journal Articles

Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors

Blood (2010) 116 (19): 4007–4015.

https://doi.org/10.1182/blood-2010-01-261958

Published: 2010

Includes: Supplemental data

Journal Articles

A Dose Escalation Trial of Imatinib for Steroid Dependent Chronic Graft-Versus-Host Disease with Anti-PDGFRA Antibody Analysis.

George L. Chen, MD, Sally Arai, MD, Mary E.D. Flowers, MD, Joanne Otani, RN, MSN, Ethan C. Cheng, Alex McMillan, PhD, Wen-Kai Weng, MD, PhD, Judith Shizuru, PhD, MD, Laura Johnston, MD, David Miklos, MD, PhD

Blood (2009) 114 (22): 3304.

https://doi.org/10.1182/blood.V114.22.3304.3304

Published: 2009

Journal Articles

Modeling Chronic Graft-Versus-Host-Disease: A New MHC-Matched Model of Late-Onset Scleroderma After Low-Dose Conditioning and Hematopoietic Cell Transplantation That Affects Only Male Recipients of Female Grafts.

Antonia MS Mueller, David Miklos, MD, PhD, Judith Shizuru, PhD, MD

Blood (2009) 114 (22): 3560.

https://doi.org/10.1182/blood.V114.22.3560.3560

Published: 2009

Journal Articles

Prophylactic Rituximab after Reduced Intensity Conditioning Transplantation Results in Low Chronic Gvhd

Sally Arai, MD, Bita Sahaf, Carol Jones, James Zhender, Robert Lowsky, Samuel Strober, Judith Shizuru, Robert Negrin, Laura Johnston, Ginna Laport, Joanna Schaenman, Janice Brown, Wen-Kai Weng, Renee Letsinger, Ruby Wong, Philip Lavori, David Miklos

Blood (2008) 112 (11): 466.

https://doi.org/10.1182/blood.V112.11.466.466

Published: 2008

Journal Articles

Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis in Myeloablative, Matched Related Donor Hematopoietic Cell Transplantation

Laura Johnston, Mareike Florek, Randall Armstrong, Jeannine S McCune, Sally Arai, Ginna Laport, Robert Lowsky, David Miklos, Judith Shizuru, Wen-Kai Weng, Kevin Sheehan, Philip Lavori, Robert Negrin

Blood (2008) 112 (11): 4348.

https://doi.org/10.1182/blood.V112.11.4348.4348

Published: 2008

NARROW

A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia

Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease

Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease

Ibrutinib for chronic graft-versus-host disease after failure of prior therapy

Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-β production

Allogeneic Transplants from HLA-Mismatched Unrelated Donors Using Total Lymphoid Irradiation and Antithymocyte Globulin Conditioning Retain a Low Risk of Graft-Versus-Host Disease and Non-Relapse Mortality with at Least As Potent Anti-Tumor Activity As with Matched Unrelated Donors

A Phase I Study of Donor Regulatory T Cells As Treatment for Steroid Dependent/Refractory Chronic Graft Versus Host Disease

Multicenter Open-Label Phase 2 Study of Ibrutinib in Chronic Graft Versus Host Disease (cGVHD) after Failure of Corticosteroids

Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematologic Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation

Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1

Donor-Derived CIK Cell Infusion As Consolidative Therapy after Non-Myeloablative Allogeneic Transplant in Patients with Myeloid Neoplasms

Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing

Chronic Graft-Versus-Host Disease Responds to Imatinib and Pre Transplant/Donor Anti-PDGFRA Antibodies Predict for Chronic Graft-Versus-Host Disease Development

Protein Microarrays Identify Elevated Allogeneic Antibodies In Association with Extensive Chronic Graft Versus Host Disease

Chronic Gvhd Global Severity According to NIH Consensus Criteria: Results From the Chronic Gvhd Consortium

Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors

A Dose Escalation Trial of Imatinib for Steroid Dependent Chronic Graft-Versus-Host Disease with Anti-PDGFRA Antibody Analysis.

Modeling Chronic Graft-Versus-Host-Disease: A New MHC-Matched Model of Late-Onset Scleroderma After Low-Dose Conditioning and Hematopoietic Cell Transplantation That Affects Only Male Recipients of Female Grafts.

Prophylactic Rituximab after Reduced Intensity Conditioning Transplantation Results in Low Chronic Gvhd

Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis in Myeloablative, Matched Related Donor Hematopoietic Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only